Literature DB >> 19561320

Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.

Christopher A Klebanoff1, Zhiya Yu, Leroy N Hwang, Douglas C Palmer, Luca Gattinoni, Nicholas P Restifo.   

Abstract

Naive and memory CD8(+) T cells can undergo programmed activation and expansion in response to a short T-cell receptor stimulus, but the extent to which in vitro programming can qualitatively substitute for an in vivo antigen stimulation remains unknown. We show that self-/tumor-reactive effector memory CD8(+) T cells (T(EM)) programmed in vitro either with peptide-pulsed antigen-presenting cells or plate-bound anti-CD3/anti-CD28 embark on a highly stereotyped response of in vivo clonal expansion and tumor destruction nearly identical to that of vaccine-stimulated T(EM) cells. This programmed response was associated with an interval of antigen-independent interferon-gamma (IFN-gamma) release that facilitated the dynamic expression of the major histocompatibility complex class I restriction element H-2D(b) on responding tumor cells, leading to recognition and subsequent tumor lysis. Delaying cell transfer for more than 24 hours after stimulation or infusion of cells deficient in IFN-gamma entirely abrogated the benefit of the programmed response, whereas transfer of cells unable to respond to IFN-gamma had no detriment to antitumor immunity. These findings extend the phenomenon of a programmable effector response to memory CD8(+) T cells and have major implications for the design of current adoptive-cell transfer trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19561320      PMCID: PMC2738567          DOI: 10.1182/blood-2008-12-192419

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

Review 1.  Immunotherapeutic approaches for hematologic malignancies.

Authors:  Michael A Caligiuri; Andrea Velardi; David A Scheinberg; Ivan M Borrello
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2004

2.  Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens.

Authors:  W W Overwijk; D R Surman; K Tsung; N P Restifo
Journal:  Methods       Date:  1997-06       Impact factor: 3.608

3.  Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.

Authors:  Douglas C Palmer; Sanjeeve Balasubramaniam; Ken-Ichi Hanada; Claudia Wrzesinski; Zhiya Yu; Shahram Farid; Marc R Theoret; Leroy N Hwang; Christopher A Klebanoff; Luca Gattinoni; Allan L Goldstein; James C Yang; Nicholas P Restifo
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

4.  Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

Authors:  L Rivoltini; K C Barracchini; V Viggiano; Y Kawakami; A Smith; A Mixon; N P Restifo; S L Topalian; T B Simonis; S A Rosenberg
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

5.  Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.

Authors:  Daniel J Powell; Mark E Dudley; Paul F Robbins; Steven A Rosenberg
Journal:  Blood       Date:  2004-09-02       Impact factor: 22.113

6.  Immune response in mice that lack the interferon-gamma receptor.

Authors:  S Huang; W Hendriks; A Althage; S Hemmi; H Bluethmann; R Kamijo; J Vilcek; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

7.  Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation.

Authors:  Ginna G Laport; Bruce L Levine; Edward A Stadtmauer; Stephen J Schuster; Selina M Luger; Stephan Grupp; Nancy Bunin; Frank J Strobl; Julio Cotte; Zhaohui Zheng; Brian Gregson; Patricia Rivers; Robert H Vonderheide; David N Liebowitz; David L Porter; Carl H June
Journal:  Blood       Date:  2003-05-22       Impact factor: 22.113

8.  T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.

Authors:  W Böhm; S Thoma; F Leithäuser; P Möller; R Schirmbeck; J Reimann
Journal:  J Immunol       Date:  1998-07-15       Impact factor: 5.422

9.  In vivo reexpression of H-2 antigens in B16 melanoma cells.

Authors:  P L Lollini; M P Colombo; C De Giovanni; G Nicoletti; G Parmiani; G Prodi; P Nanni
Journal:  Exp Clin Immunogenet       Date:  1985

10.  Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.

Authors:  Rong Zeng; Rosanne Spolski; Steven E Finkelstein; SangKon Oh; Panu E Kovanen; Christian S Hinrichs; Cynthia A Pise-Masison; Michael F Radonovich; John N Brady; Nicholas P Restifo; Jay A Berzofsky; Warren J Leonard
Journal:  J Exp Med       Date:  2005-01-03       Impact factor: 14.307

View more
  19 in total

Review 1.  Therapeutic cancer vaccines: are we there yet?

Authors:  Christopher A Klebanoff; Nicolas Acquavella; Zhiya Yu; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.

Authors:  Jacob S Bowers; Michelle H Nelson; Sreenath Kundimi; Stefanie R Bailey; Logan W Huff; Kristina M Schwartz; David J Cole; Mark P Rubinstein; Chrystal M Paulos
Journal:  Clin Cancer Res       Date:  2015-04-22       Impact factor: 12.531

3.  Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.

Authors:  Christopher A Klebanoff; Luca Gattinoni; Douglas C Palmer; Pawel Muranski; Yun Ji; Christian S Hinrichs; Zachary A Borman; Sid P Kerkar; Christopher D Scott; Steven E Finkelstein; Steven A Rosenberg; Nicholas P Restifo
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

Review 4.  Adoptive immunotherapy for cancer: harnessing the T cell response.

Authors:  Nicholas P Restifo; Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

Review 5.  NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.

Authors:  Edwin P Alyea; Daniel J DeAngelo; Jeffrey Moldrem; John M Pagel; Donna Przepiorka; Michel Sadelin; James W Young; Sergio Giralt; Michael Bishop; Stan Riddell
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-24       Impact factor: 5.742

6.  An effective mouse model for adoptive cancer immunotherapy targeting neoantigens.

Authors:  Ken-Ichi Hanada; Zhiya Yu; Gabrielle R Chappell; Adam S Park; Nicholas P Restifo
Journal:  JCI Insight       Date:  2019-05-16

7.  Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice.

Authors:  Gloria H Y Lin; Yuanqing Liu; Thanuja Ambagala; Byoung S Kwon; Pamela S Ohashi; Tania H Watts
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

8.  Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.

Authors:  Ying Xie; Akgül Akpinarli; Charles Maris; Edward L Hipkiss; Malcolm Lane; Eun-Kyung M Kwon; Pawel Muranski; Nicholas P Restifo; Paul Andrew Antony
Journal:  J Exp Med       Date:  2010-02-15       Impact factor: 14.307

9.  Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.

Authors:  Anat Globerson-Levin; Tova Waks; Zelig Eshhar
Journal:  Mol Ther       Date:  2014-02-27       Impact factor: 11.454

10.  Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion.

Authors:  Jacob S Bowers; Michelle H Nelson; Kinga Majchrzak; Stefanie R Bailey; Baerbel Rohrer; Andrew Dm Kaiser; Carl Atkinson; Luca Gattinoni; Chrystal M Paulos
Journal:  JCI Insight       Date:  2017-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.